Show simple item record

dc.contributor.authorGillessen, Silke
dc.contributor.authorBossi, Alberto
dc.contributor.authorDavis, Ian D.
dc.contributor.authorde Bono, Johann S.
dc.contributor.authorFizazi, Karim
dc.contributor.authorJames, Nicholas D.
dc.contributor.authorMottet, Nicolas
dc.contributor.authorShore, Neal
dc.contributor.authorSmall, Eric
dc.contributor.authorSmith, Mathew
dc.contributor.authorSweeney, Christopher
dc.contributor.authorTombal, Bertrand
dc.contributor.authorAntonarakis, Emmanuel S.
dc.contributor.authorAparicio, Ana M.
dc.contributor.authorArmstrong, Andrew J.
dc.contributor.authorAttard, Gerhardt
dc.contributor.authorBeer, Tomasz M.
dc.contributor.authorBeltran, Himisha
dc.contributor.authorBjartell, Anders
dc.contributor.authorBlanchard, Pierre
dc.contributor.authorBriganti, Alberto
dc.contributor.authorBristow, Rob G.
dc.contributor.authorBulbul, Muhammad
dc.contributor.authorCaffo, Orazio
dc.contributor.authorCastellano, Daniel
dc.contributor.authorCastro, Elena
dc.contributor.authorCheng, Heather H.
dc.contributor.authorChi, Kim N.
dc.contributor.authorChowdhury, Simon
dc.contributor.authorClarke, Caroline S.
dc.contributor.authorClarke, Noel W.
dc.contributor.authorDaugaard, Gedske
dc.contributor.authorDe Santis, Maria
dc.contributor.authorDuran, Ignacio
dc.contributor.authorEeles, Ros
dc.contributor.authorEfstathiou, Eleni
dc.contributor.authorEfstathiou, Jason
dc.contributor.authorEkeke, Onyeanunam
dc.contributor.authorEvans, Christopher P.
dc.contributor.authorFanti, Stefano
dc.contributor.authorFeng, Felix Y.
dc.contributor.authorFonteyne, Valerie
dc.contributor.authorFossati, Nicola
dc.contributor.authorFrydenberg, Mark
dc.contributor.authorGeorge, Daniel
dc.contributor.authorGleave, Martin
dc.contributor.authorGravis, Gwenaelle
dc.contributor.authorHalabi, Susan
dc.contributor.authorHeinrich, Daniel
dc.contributor.authorHerrmann, Ken
dc.contributor.authorHigano, Celestia
dc.contributor.authorHofman, Michael S.
dc.contributor.authorHorvath, Lisa G.
dc.contributor.authorHussain, Maha
dc.contributor.authorJereczek-Fossa, Barbara Alicja
dc.contributor.authorJones, Robert
dc.contributor.authorKanesvaran, Ravindran
dc.contributor.authorKellokumpu-Lehtinen, Pirkko-Liisa
dc.contributor.authorKhauli, Raja B.
dc.contributor.authorKlotz, Laurence
dc.contributor.authorKramer, Gero
dc.contributor.authorLeibowitz, Raya
dc.contributor.authorLogothetis, Christopher J.
dc.contributor.authorMahal, Brandon A.
dc.contributor.authorMaluf, Fernando
dc.contributor.authorMateo, Joaquin
dc.contributor.authorMatheson, David
dc.contributor.authorMehra, Niven
dc.contributor.authorMerseburger, Axel
dc.contributor.authorMorgans, Alicia K
dc.contributor.authorMorris, Michael J.
dc.contributor.authorMrabti, Hind
dc.contributor.authorMukherji, Deborah
dc.contributor.authorMurphy, Declan G.
dc.contributor.authorMurthy, Vedang
dc.contributor.authorNguyen, Paul L.
dc.contributor.authorOh, William K.
dc.contributor.authorOst, Piet
dc.contributor.authorO'Sullivan, Joe M.
dc.contributor.authorPadhani, Anwar R.
dc.contributor.authorPezaro, Carmel J
dc.contributor.authorPoon, Darren M.C.
dc.contributor.authorPritchard, Colin C.
dc.contributor.authorRabah, Danny M.
dc.contributor.authorRathkopf, Dana
dc.contributor.authorReiter, Robert E.
dc.contributor.authorRubin, Mark A.
dc.contributor.authorRyan, Charles J.
dc.contributor.authorSaad, Fred
dc.contributor.authorSade, Juan Pablo
dc.contributor.authorSartor, Oliver A.
dc.contributor.authorScher, Howard I.
dc.contributor.authorSharifi, Nima
dc.contributor.authorSkoneczna, Iwona
dc.contributor.authorSoule, Howard
dc.contributor.authorSpratt, Daniel E.
dc.contributor.authorSrinivas, Sandy
dc.contributor.authorSternberg, Cora N.
dc.contributor.authorSteuber, Thomas
dc.contributor.authorSuzuki, Hiroyoshi
dc.contributor.authorSydes, Matthew R.
dc.contributor.authorTaplin, Mary-Ellen
dc.contributor.authorTilki, Derya
dc.contributor.authorTürkeri, Levent
dc.contributor.authorTurco, Fabio
dc.contributor.authorUemura, Hiroji
dc.contributor.authorUemura, Hirotsugu
dc.contributor.authorÜrün, Yüksel
dc.contributor.authorVale, Claire L.
dc.contributor.authorvan Oort, Inge
dc.contributor.authorVapiwala, Neha
dc.contributor.authorWalz, Jochen
dc.contributor.authorYamoah, Kosj
dc.contributor.authorYe, Dingwei
dc.contributor.authorYu, Evan Y.
dc.contributor.authorZapatero, Almudena
dc.contributor.authorZilli, Thomas
dc.contributor.authorOmlin, Aurelius
dc.identifier.citationGillessen, S., Bossi, A., Davis, I.D. et al. (2023) Management of patients with advanced prostate cancer. Part I: Intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. European Urology, 83(3), pp. 267-293.en
dc.identifier.pmid36494221 (pubmed)
dc.description© 2023 The Authors. Published by Elsevier on behalf of European Association of Urology. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website:
dc.description.abstractBackground: Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management. Objective: To present consensus voting results for select questions from APCCC 2022. Design, setting, and participants: Before the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiple-choice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members (“panellists”) who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1–3. Outcome measurements and statistical analysis: Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. Results and limitations: The voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis. Conclusions: These voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical management for which high-level evidence is scant or conflicting. The findings can also help funders and policymakers prioritise areas for future research. Diagnostic and treatment decisions should always be individualised based on patient and cancer characteristics (disease extent and location, treatment history, comorbidities, and patient preferences) and should incorporate current and emerging clinical evidence, therapeutic guidelines, and logistic and economic factors. Enrolment in clinical trials is always strongly encouraged. Importantly, APCCC 2022 once again identified important gaps (areas of nonconsensus) that merit evaluation in specifically designed trials. Patient summary: The Advanced Prostate Cancer Consensus Conference (APCCC) provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference aims to share the knowledge of international experts in prostate cancer with health care providers and patients worldwide. At each APCCC, a panel of physician experts vote in response to multiple-choice questions about their clinical opinions and approaches to managing advanced prostate cancer. This report presents voting results for the subset of questions pertaining to intermediate- and high-risk and locally advanced prostate cancer, biochemical relapse after definitive treatment, advanced (next-generation) imaging, and management of side effects caused by hormonal therapies. The results provide a practical guide to help clinicians and patients discuss treatment options as part of shared multidisciplinary decision-making. The findings may be especially useful when there is little or no high-level evidence to guide treatment decisions.en
dc.description.sponsorshipWe gratefully acknowledge the following organisations for providing financial support for the APCCC 2022: The City of Lugano and Movember Foundation. Ros Eeles is supported by a National Institute of Health Research grant to the Biomedical Research Centre at The Institute of Cancer Research and Royal Marsden NHS Foundation Trust. We also acknowledge sponsorship from several for-profit organisations for APCCC 2022, including Advanced Accelerator Applications, Amgen, Astellas, AstraZeneca, Bayer Health Care, Debiopharm, MSD, Janssen Oncology, Myovant Sciences, Orion Pharma, Pfizer Oncology, Roche, Telix Innovations SA, Ferring Pharmaceuticals, Lantheus, and Tolmar. These for-profit organisations supported the conference financially but had no input on the scientific content or the final publication.en
dc.rightsLicence for published version: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
dc.subjectprostate canceren
dc.subjectside effectsen
dc.subjectadjuvant therapyen
dc.subjectbiochemical recurrenceen
dc.subjecthormonal treatmenten
dc.subjectlocally advanced prostate canceren
dc.subjectnext-generation imagingen
dc.subjectprostate-specific membrane antigen positron emission tomography imagingen
dc.subjectsalvage radiation therapyen
dc.subjectsalvage therapyen
dc.titleManagement of patients with advanced prostate cancer. Part I: Intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022en
dc.typeConference contributionen
dc.identifier.journalEuropean Urologyen
dc.contributor.institutionOncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Università della Svizzera Italiana, Lugano, Switzerland. Electronic address:
rioxxterms.funderCity of Lugano and Movember Foundation, National Institute of Health Researchen
dc.description.versionAccepted version

Files in this item

Publisher version

This item appears in the following Collection(s)

Show simple item record

Licence for published version: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Licence for published version: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International